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Background: Treatment of the primary, termed local therapy (LT), may improve survival
in metastatic prostate cancer (mPCa) versus no local therapy (NLT).
Objective: To assess cancer-speciﬁc mortality (CSM) after LT versus NLT in mPCa.
Design, setting, and participants: Within the Surveillance, Epidemiology and End
Results database (2004–2013), 13 692 mPCa patients were treated with LT (radical
prostatectomy [RP] or radiation therapy [RT]) or NLT.
Outcome measurements and statistical analysis: Multivariable competing risk regression analyses (MVA CRR) tested CSM after propensity score matching (PSM) in two
analyses, (1) NLT versus LT and (2) RP versus RT, and were complemented with
interaction, sensitivity, unmeasured confounder, and landmark analyses.
Results and limitations: Of 13 692 mPCa patients, 474 received LT: 313 underwent RP
and 161 RT. In MVA CRR, after PSM, LT (n = 474) results in lower CSM (subhazard ratio
[SHR] 0.40, 95% conﬁdence interval [CI] 0.32–0.50) versus NLT (n = 1896). In MVA CRR
after PSM, RP (n = 161) results in lower CSM (SHR 0.59, 95% CI 0.35–0.99) versus RT
(n = 161). Invariably, lowest CSM rates were recorded for Gleason 7, cT3, and
M1a substage. Interaction and sensitivity analyses conﬁrmed the robustness of
results, and landmark analyses rejected the bias favouring LT. A strong unmeasured
confounder (HR = 5), affecting 30% of NLT patients, could obliterate LT beneﬁt. Data
were retrospective.
Conclusions: In mPCa, LT results in lower mortality relative to NLT. Within LT, lower
mortality is recorded after RP than RT. Patients with most favourable grade, local stage,
and metastatic substage derive most beneﬁt from LT. They also derive most beneﬁt from
RP, when LT types are compared (RP vs RT). It is important to consider study limitations
until ongoing clinical trials conﬁrm the proposed beneﬁts.
Patient summary: Individuals with prostate cancer that spreads outside of the prostate
might still beneﬁt from prostate-directed treatments, such as radiation or surgery, in
addition to receiving androgen deprivation therapy.
# 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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1.

Introduction

119

sufﬁcient matching. Propensity score matching (1:1 ratio due to sample
size) was repeated for RT versus RP tests.

Treatment of the primary tumour, termed local treatment
(LT), reduces mortality rates in several malignancies (renal,
colon, and ovarian cancer), despite established metastatic
spread [1–6]. LT may also improve survival in metastatic
prostate cancer (mPCa), relative to standard of care:
androgen deprivation therapy (ADT) with no LT (NLT)
[7]. Evidence stems from six studies within four data
repositories: the Surveillance, Epidemiology and End Results
(SEER) database [8–10], the SEER-Medicare database [11],
the National Cancer Database (NCDB) [12], and the Munich
Cancer Registry [13]. Four studies reported improved
survival with radical prostatectomy (RP) versus NLT
[8,9,11,13]. However, none directly examined RP against
radiotherapy (RT). Additionally, three institutional studies
confirmed RP safety in select mPCa patients [14–16].
Methodological limitations apply to all six reports: four
failed to account for other-cause mortality that may
irreversibly confound all-cause mortality rates and lacked
competing risk regression (CRR) [8,10,12,13]. Three failed to
fully adjust for patient characteristics with propensity score
matching [9,13]. One combined CRR and propensity score
matching but had a limited sample size: 47 RP patients [11].
We combined CRR with propensity score matching,
within the largest possible patient sample: the SEER
database to test for differences in CSM according to LT
versus NLT. Moreover, unlike previously, we tested for CSM
differences according to LT type: RP versus RT.
2.

Patients and methods

2.1.

Patient selection

Within the SEER database (18 cancer registries, accounting for 26% of the
US population), we identiﬁed patients diagnosed with adenocarcinoma
of the prostate (International Classiﬁcation of Disease for Oncology
[61.9]; histological code: 8140) with metastatic disease at diagnosis
(ie, SEER ﬁeld ‘‘CS Mets at DX’’) and stages M1a–c (sixth edition of
American Joint Committee on Cancer [AJCC] Cancer Staging Manual). All
underwent LT: (1) RP (surgery site codes 50 and 70) with or without RT
or (2) RT (ie, brachytherapy) with or without external beam radiation
therapy (EBRT) or (3) NLT, between 2004 and 2013. Prostate-speciﬁc
antigen (PSA) values were available for patients diagnosed between
2010 and 2013, and were included in subgroup analysis.
Patients were stratiﬁed according to RP versus RT versus NLT status, as
described earlier [8,9]. EBRT was excluded; it lacked target site
information distinguishing local from extraprostatic treatment. Other
surgical treatments than RP, for example, transurethral resection of
the prostate, were also excluded. These selection criteria yielded
13 692 patients.

2.2.

Propensity score matching

Propensity score matching (4:1 ratio, with nearest-neighbour matching or
calliper width of 0.1 of the standard deviation of the logit) yielded similar
patient characteristics between LT (n = 474) and NLT cohorts (n = 13 218),
emulated randomised trial design, minimised residual bias, and increased
precision [17]. Adjustment variables consisted of age, race, biopsy Gleason
score, clinical tumour stage, nodal stage, and metastatic substages.
Standardised mean difference measurements were performed to conﬁrm

2.3.

Statistical analyses

To ensure intergroup comparability, we exclusively relied on metrics
applicable to all patients, regardless of LT versus NLT status or of LT type
(RP vs RT): biopsy Gleason score, clinical tumour, nodes, and metastatic
substages were used in propensity score matching and in all analyses.
Covariates consisted of age, race, marital status, biopsy Gleason
score, clinical tumour, nodes, and metastatic substages. Subsequently,
clinical variables that qualiﬁed as independent cancer-speciﬁc mortality
(CSM) predictors were used in a risk stratiﬁcation scheme of 1 versus
2 risk factors. To further examine the effect of risk factors (1 vs 2 risk
factors), we reﬁtted the Cox model by adding an interaction term: risk
stratiﬁcation scheme and treatment status. Landmark analyses were
performed at 6, 12, 18, and 24 mo after the time of diagnosis, to address
the potential effect of immortal time bias, which may favourably affect
patients treated with either RP or RT, relative to NLT patients
[18]. Sensitivity analyses tested the effect of a potential unmeasured
confounder by (1) computing the prevalence required to render our
result statistically insigniﬁcant assuming that such a confounder has a
moderate subhazard ratio (SHR; eg, 2), and (2) computing the SHR
required to render our results statistically insigniﬁcant assuming a
moderate prevalence ratio (eg, 30% in LT and 10% in NLT) [19,20].
All tests were two sided with a statistical signiﬁcance set at
p < 0.05. Analyses were performed with the statistical package for R
(version 3.2.2; the R foundation for Statistical Computing, Vienna, Austria).

3.

Results

Prior to propensity score matching, NLT patients were
oldest (72 yr), relative to RT (68 yr) and RP patients (63 yr,
Tables 1 and 2). The rate for biopsy Gleason score 7 was
lowest in NLT patients (18%), followed by RP (47%) and RT
patients (48%). The rate for clinical stage T3 was highest in
RP (97%), followed by in RT (94%) and NLT (89%) patients.
Node stage N0/NX was virtually the same in RP (92%) and RT
(91%) patients and lower in NLT patients (80%). Finally,
metastatic substage M1a was also virtually the same in RP
(11%) and RT (12%) patients and lower in NLT group (6.1%).
After propensity score matching (NLT vs LT and RP vs RT),
residual statistically significant differences remained only
for year of diagnosis in RP versus RT comparisons: 17% and
6.2% of the population in year 2013, respectively, in RP and
RT arms. After propensity score matching, the median
follow-up of NLT versus LT and RP versus RT patients
without CSM or other-cause mortality was 31.0 mo
(interquartile range [IQR] 12.0–58.0) versus 43.5 (IQR
18.0–80.0) and 39.0 mo (IQR 16–72) versus 56.0 mo (IQR
28.0–86.0), respectively.
In propensity score–matched multivariable competing
risk regression analyses (MVA CRR), both LT types, RP and
RT, yielded lower CSM rates (65% and 52%, respectively)
relative to NLT (SHR 0.35, 95% CI 0.26–0.46 and SHR 0.48,
95% CI 0.35–0.66; both p < 0.001; Table 3). Additionally,
CSM was also lower with Gleason 7 (vs GS 8; SHR 1.84,
95% CI 1.59–2.13; p < 0.001), cT3 (vs T4; SHR 1.85, 95% CI
1.39–2.46; p < 0.001), and substage M1a (vs M1c; SHR 1.98,
95% CI 1.52–2.58; p < 0.001) and in married men (vs
divorced/widowed; SHR 1.25, 95% CI 1.03–1.51; p < 0.024).
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Table 1 – Descriptive characteristics of 13 692 patients diagnosed with metastatic prostate cancer between 2004 and 2013 from the
Surveillance Epidemiology and End Results database, stratified according to treatment type with and without propensity score matching
(ratio 4:1)
Variables

Median age, yr (IQR)
Race, n (%)
Caucasian
African American
Other
Unknown
Marital status, n (%)
Married
Divorced/widowed
Single
Unknown
Year of diagnosis, n (%)
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
Biopsy Gleason score, n (%)
6
7
8
Unknown
Clinical T stage, n (%)
T1c
T2
T3
T4
Clinical N stage, n (%)
N0/Nx
N1
AJCC M Stage, n (%)
M1a
M1b
M1c
PSA at biopsy, ng/ml, n (%) c
20
>20
Cancer-speciﬁc death, n (%)

No local treatment
(n = 13 218; %)

Local treatment
(n = 474; %)

p value

72 (63–80)

64 (58–69)

0.01
0.6

9765 (74)
2521 (19)
799 (6.0)
133 (1.0)

352 (74)
85 (18)
34 (7.2)
3 (0.6)

7347
2799
2049
1023

(56)
(21)
(16)
(7.7)

348 (73)
63 (13)
39 (8.2)
24 (5.1)

1190
1187
1215
1250
1307
1323
1384
1337
1462
1563

(9.0)
(9.0)
(9.2)
(9.5)
(9.9)
(10)
(11)
(10)
(11)
(12)

40
43
57
44
59
44
38
49
47
53

a

Propensity
score-adjusted
no local treatment
(n = 1896; %)

Propensity
score-adjusted
local treatment
(n = 474; %)

64 (57–70)

64 (58–69)

1430 (75)
341 (18)
106 (5.6)
19 (1.0)

352 (74)
85 (18)
34 (7.2)
3 (0.6)

1379 (73)
266 (14)
149 (7.9)
102 (5.4)

348 (73)
63 (13)
39 (8.2)
24 (5.1)

199
180
184
192
197
193
188
185
184
194

(11)
(9.5)
(9.7)
(10)
(10)
(10)
(9.9)
(9.8)
(9.7)
(10)

40
43
57
44
59
44
38
49
47
53

247
611
894
144

(13)
(32)
(47)
(7.6)

71 (15)
152 (32)
217 (46)
34 (7.2)

959 (51)
721 (38)
137 (7.2)
79 (4.2)

246 (52)
171 (36)
36 (7.6)
21 (4.4)

1749 (92)
147 (7.8)

435 (92)
39 (8.2)

180 (9.5)
1341 (71)
375 (20)

54 (11)
325 (69)
95 (20)

124 (71)
50 (29)
779 NA

128 (74)
46 (26)
94 NA

<0.001

71 (15)
152 (32)
217 (46)
34 (7.2)

6279
4318
1199
1422

246 (52)
171 (36)
36 (7.6)
21 (4.4)

0.6

0.7

0.9

<0.001
(48)
(33)
(9.1)
(11)

0.8

<0.001
10596 (80)
2622 (20)

435 (92)
39 (8.2)

800 (6.1)
9478 (72)
2940 (22)

54 (11)
325 (69)
95 (20)

864 (17)
4249 (83)
5920 NA

128 (74)
46 (26)
94 NA

0.4

<0.001

0.7

<0.001

NA

0.059
0.5

(8.4)
(9.1)
(12)
(9.3)
(13)
(9.3)
(8.0)
(10)
(9.9)
(11)

<0.001
453 (3.4)
1888 (14)
7270 (55)
3607 (27)

b

>0.9

0.3
(8.4)
(9.1)
(12)
(9.3)
(13)
(9.3)
(8.0)
(10)
(9.9)
(11)

p value

NA

IQR = interquartile range; AJCC = American Joint Committee on Cancer; NLT = no local treatment; LT = local treatment; NA = not applicable; PSA = prostatespeciﬁc antigen.
a
Comparing NLT versus LT (unmatched).
b
Comparing NLT versus LT (propensity score-adjusted cohorts).
c
PSA values were available only for patients diagnosed between 2010 and 2013; proportions presented are of the corresponding subgroups.

Using interaction term analyses, we tested whether
treatment type (RT or RP vs NLT) interacts with independent predictors of CSM (Gleason 8, cT4, M1b–c substages) that were stratified as 1 variable versus 2
variables, and are henceforth referred to as risk criteria.
The interaction term analyses revealed the following: (1)
both RP and RT have a strong protective effect in patient
with 1 risk criterion (SHR of RP: 0.16, 95% CI 0.09–.28;
SHR of RT: 0.33, 95% CI 0.19–0.56; Supplementary
Table 1), and (2) RP and RT are less effective in patients
with 2 risk criteria than those with 1 risk criterion

(SHR of interaction term between RP and 2 risk criteria:
3.95, 95% CI 2.02–7.67; SHR of interaction term between
RT and 2 risk criteria: 2.08, 95% CI 1.07–4.04; Supplementary Table 1). Based on the result of the interaction
term analyses, and to further investigate whether RP
and RT have a protective effect in those with 2 risk
criteria, we conducted a subgroup analysis only in
patients with 2 risk factors. Here, the central tendency
for RP and RT suggests that even in patients with 2 risk
factors, LT is still protective (SHR of RP: 0.60; SHR of
RT: 0.67).
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Table 2 – Descriptive characteristics of 474 locally treated patients diagnosed with metastatic prostate cancer between 2004 and 2013 from
the Surveillance Epidemiology and End Results database, stratified according to treatment type with and without propensity score matching
(ratio 1:1)
Variables

Median age, yr (IQR)
Race, n (%)
Caucasian
African American
Other
Unknown
Marital status, n (%)
Married
Divorced/widowed
Single
Unknown
Year of diagnosis, n (%)
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
Biopsy Gleason score, n (%)
6
7
8
Unknown
Clinical T stage, n (%)
T1c
T2
T3
T4
Clinical N stage, n (%)
N0/Nx
N1
AJCC M Stage, n (%)
M1a
M1b
M1c
Cancer-speciﬁc death, n (%)

Radical prostatectomy
(n = 313; %)

Radiotherapy
(n = 161; %)

63 (58–67)

68 (60–73)

237 (76)
48 (15)
26 (8.3)
2 (0.6)

115 (71)
37 (23)
8 (5.0)
1 (0.6)

237 (76)
38 (12)
24 (7.7)
14 (4.5)

111 (69)
25 (16)
15 (9.3)
10 (6.2)

23
25
29
27
39
30
28
31
38
43

17 (11)
18 (11)
28 (17)
17 (11)
20 (12)
14 (8.7)
10 (6.2)
18 (11)
9 (5.6)
10 (6.2)

p value

>0.9
0.15

a

Propensity
score-adjusted
radical prostatectomy
(n = 161; %)

Propensity
score-adjusted
radiotherapy
(n = 161; %)

66 (60–71)

68 (60–73)

119 (74)
24 (15)
16 (9.9)
2 (1.2)

115 (71)
37 (23)
8 (5.0)
1 (0.6)

110 (68)
31 (19)
13 (8.1)
7 (4.4)

111 (69)
25 (16)
15 (9.3)
10 (6.2)

15
12
16
10
18
13
15
19
15
28

(9.3)
(7.5)
(9.9)
(6.2)
(11)
(8.1)
(9.3)
(12)
(9.3)
(17)

17 (11)
18 (11)
28 (17)
17 (11)
20 (12)
14 (8.7)
10 (6.2)
18 (11)
9 (5.6)
10 (6.2)

29
45
77
10

(18)
(28)
(48)
(6.2)

30
47
72
12

(19)
(29)
(45)
(7.5)

78
58
14
11

(49)
(36)
(8.7)
(6.8)

83
54
14
10

(52)
(34)
(8.7)
(6.2)

0.5

30
47
72
12

(19)
(29)
(45)
(7.5)

163 (52)
117 (37)
22 (7.0)
11 (3.5)

83
54
14
10

(52)
(34)
(8.7)
(6.2)

288 (92)
25 (8.0)

147 (91)
14 (8.7)

35 (11)
222 (71)
56 (18)
52 NA

19 (12)
103 (64)
39 (24)
42 NA

>0.9

0.5

>0.9

0.9

0.8
149 (93)
12 (7.5)

147 (91)
14 (8.7)

23 (14)
102 (63)
36 (22)
25 NA

19 (12)
103 (64)
39 (24)
42 NA

0.2

NA

0.4
0.12

0.04

0.4
41 (13)
105 (34)
145 (46)
22 (7.0)

b

0.7

0.02
(7.4)
(8.0)
(9.3)
(8.6)
(13)
(9.6)
(9.0)
(9.9)
(12)
(14)

p value

0.8

IQR = interquartile range; AJCC = American Joint Committee on Cancer; NLT = no local treatment; LT = local treatment; NA = not applicable.
Comparing NLT versus LT (unmatched).
b
Comparing NLT versus LT (propensity score-adjusted cohorts).
a

To test the potential effect of baseline PSA values, we
repeated the analyses in individuals with available PSA
data. Propensity score matching (1:1) for clinical parameters and PSA values resulted in 348 assessable mPCa
patients (174 NLT and 174 LT). Here, MVA CRR showed that
LT yields lower CSM (51%) versus NLT (SHR 0.49, 95% CI
0.28–0.86; p = 0.012), as in the main analysis.
To address the effect of potential nonadherence to ADT
use in mPCa patients, we performed interaction analyses
where age, categorised as younger versus older (70
vs > 70 yr age) interacted with treatment type. We posited
that in younger mPCa patients, nonadherence to ADT should
not exist. According to the results of the interaction term
analysis, where age 70 yr was set as a reference, the effect
of LT relative to NLT was virtually the same: RP and RT

yielded lower CSM (68% and 52%, respectively) compared
with NLT (SHR 0.32, 95% CI 0.23–0.45 and SHR 0.48, 95% CI
0.32–0.72; both p < 0.001).
In landmark analyses performed at 6, 12, 18, and 24 mo
after LT, the decrease in CSM recorded after RP, as well as
after RT, remained unchanged relative to ‘‘naive’’ analyses,
where the potentially favourable survival bias towards
individuals who benefited from LT was unaccounted for.
We also tested for the effect of an unmeasured
confounder that could obliterate the effect of LT on CSM.
The analyses revealed that an unmeasured confounder with
an SHR of 2 would render the effect of LT statistically
insignificant, if it affected 70% of NLT patients and  10%
of LT patients. We tested a second scenario, where an
unmeasured confounder with an SHR of 5 would render
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Table 3 – Multivariable competing risks regression of propensity
score-adjusted patients diagnosed with metastatic prostate cancer
between 2004 and 2013 from the Surveillance Epidemiology and
End Results database, stratified according to treatment type
Variables

Local treatment versus no local
treatment
SHR (95% CI)

Table 4 – Multivariable competing risks regression of propensity
score-adjusted patients diagnosed with metastatic prostate cancer
and locally treated between 2004 and 2013 from the Surveillance
Epidemiology and End Results database, stratified according to
treatment type
Variables

Radical prostatectomy versus
radiotherapy

p value
SHR (95% CI)

Type of treatment
No local therapy
Radiotherapy
Radical prostatectomy
Biopsy Gleason score
7
8
Unknown
Clinical T stage
T1/T2
T3
T4
Clinical N stage
N0/Nx
N1
AJCC M stage
M1a
M1b
M1c
Age (yr)
Race
Caucasian
African American
Other/unknown
Marital status
Married
Divorced/widowed
Single
Unknown

Ref.
0.48 (0.35–0.66)
0.35 (0.26–0.46)

<0.001
<0.001

Ref.
1.84 (1.59–2.13)
1.72 (1.28–2.31)

<0.001
<0.001

Ref.
1.10 (0.87–1.40)
1.85 (1.39–2.46)

0.4
<0.001

Ref.
1.18 (0.91–1.52)

0.20

Ref.
1.65 (1.31–2.08)
1.98 (1.52–2.58)
1.00 (0.99–1.01)

<0.001
<0.001
0.4

Ref.
0.91 (0.76–1.09)
0.77 (0.58–1.02)

0.3
0.07

Ref.
1.25 (1.03–1.51)
1.23 (0.97–1.57)
0.75 (0.54–1.03)

0.024
0.092
0.074

CI = conﬁdence
interval;
SHR = subhazard
AJCC = American Joint Committee on Cancer.

ratio;

Ref. = reference;

the effect of LT statistically insignificant, if it affected 30%
of NLT patients and  10% of LT patients.
In propensity score–matched MVA CRR testing RP versus
RT CSM differences, RP yielded lower CSM (41%) relative to
RT (SHR 0.59, 95% CI 0.35–0.99; p = 0.048; Table 4).
Additionally, CSM was also lower in presence of Gleason
7 (vs GS 8; SHR 3.67, 95% CI 2.03–6.66; p < 0.001), cT3
(vs T4; SHR 5.48, 95% CI 2.64–11.4; p < 0.001), and M1a
substage (vs M1c; SHR 4.7, 95% CI 1.88–11.7; p < 0.001).
4.

Discussion

In mPCa, LT showed a survival benefit compared with NLT in
six retrospective studies [8–13]. However, methodological
limitations [9,10,13] and/or lack of adjustment for othercause mortality [8,10,12,13] limits their validity. Sample
size limitations (eg, only 47 RP patients were included)
undermine the generalisability of the single study that
combined the necessary methodological tools: CRR and
propensity score matching [11]. Last but not least, no study
directly compared RP with nonsurgical LT, that is, RT. Based
on those limitations, we tested CSM rates using the most
bias-free approach, namely, with the combined use of CRR

Type of treatment
Radiotherapy
Radical prostatectomy
Biopsy Gleason score
7
8
Unknown
Clinical T stage
T1/T2
T3
T4
Clinical N stage
N0/Nx
N1
AJCC M stage
M1a
M1b
M1c
Age (yr)

p value

Ref.
0.59 (0.35–0.99)

0.048

Ref.
3.67 (2.03–6.66)
0.80 (0.14–4.72)

<0.001
0.8

Ref.
1.01 (0.39–2.61)
5.48 (2.64–11.4)

>0.9
<0.001

Ref.
1.01 (0.34–2.99)

>0.9

Ref.
3.48 (1.51–8.04)
4.70 (1.88–11.7)
1.02 (0.98–1.05)

0.01
<0.001
0.3

CI = conﬁdence
interval;
SHR = subhazard
AJCC = American Joint Committee on Cancer.

ratio;

Ref. = reference;

accounting for other-cause mortality and propensity score
matching. Several noteworthy findings emerged.
First, we identified important and highly clinically
meaningful differences between NLT and LT cohorts, as
well as between RP and RT cohorts. Such differences
validate the necessity of propensity score matching, which
we applied. Moreover, such differences may not rest only on
measured variables that are available for analyses. Instead,
unmeasured confounders that are not accounted for by
recorded variables also require attention. We addressed
that need and showed that it is unlikely that an unmeasured
confounder could negate the benefit of LT versus NLT.
Second, our MVA demonstrated important and highly
statistically significant survival benefit, when LT was
compared with NLT. The CSM benefit withstood the rigours
of increasingly complex hypothesis testing: sensitivity and
landmark analyses. Both failed to corroborate the CSM
decrease associated with LT, in patients with 2 risk
criteria. Hence, there is a need for careful risk stratification.
Interestingly, landmark analyses performed at 6, 12, 18, and
24 mo after LT failed to show that patients selected for LT,
either RP or RT, have benefited from a favourable survival
bias.
Third, our MVA also demonstrated important and
statistically significant survival benefit, expressed in CSM
reduction, when RP was compared with RT. In both
analyses, LT versus NLT and RP versus RT, the lowest
CSM rates were recorded in patients with Gleason 7, cT3,
or M1a substage. In consequence, important selection
considerations are required, and patients with favourable
grade, stage, and low metastatic burden should only be
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considered, as is recommended in ongoing prospective
trials (NCT02454543, NCT02458716, and NCT01751438).
Fourth, our results emphasised the importance of risk
stratification within the LT versus NLT cohort, as well as
within the RP versus RT cohort. For example, interaction
term analyses showed that RT and RP are less effective in
patients with 2 risk criteria compared with those with 1
risk criterion. Similarly, in the comparison between RP and
RT patients, the CSM benefit was not observed in patients
with 2 risk criteria.
Fifth, our results corroborate the findings based on the
same and other data repositories, namely the SEER [8–10],
SEER-Medicare [11], NCDB [12], and Munich Cancer registry
[13]. However, none of those four comparisons directly
examined RP against RT, as was done in the current study.
Survival advantage related to LT delivery in select mPCa
patients was also recently reported in a German case–
control study with a small sample size (n = 23) [15]. RP was
limited to mPCa patients treated with ADT, with minimal
extent of bone metastases, with limited extent of lymph
node metastases, and without visceral involvement. RP
patients experienced similar complication rates to patients
treated with ADT alone.
Our study is not devoid of limitations. First, similar to all
previous studies, this study is retrospective in nature.
Currently, three prospective clinical trials addressing
RP in the metastatic setting are open (NCT02454543,
NCT02458716, and NCT01751438). Second, the SEER database does not provide information on comorbidities and/or
performance status, which may be used for patient selection.
Third, post-treatment PSA values are available only in some
SEER database patients. They represent important prognostic
markers, and favourable post-ADT PSA responses might have
represented an argument for stronger consideration of LT.
Similarly, baseline PSA represents an independent risk factor
for CSM. Indeed, the protective association of RP with CSM in
mPCa patients was previously not recorded in patients with
baseline PSA levels above 20 ng/ml [11]. Fourth, site-specific
EBRT codes are unavailable in the SEER database and only
brachytherapy codes were analyzed. Fifth, the SEER database
does not provide complete information regarding the exact
extent, for example, number and/or site(s) of metastatic
disease, except for M substages that were included in all
analyses [21]. Finally, data regarding systemic therapies,
such as ADT [22], chemotherapy, or agents targeting the
androgen receptor and/or autocrine/paracrine androgen
synthesis, were also unavailable. In the United States, during
the study span and until today, ADT represents the gold
standard therapy for men with mPCa, as per National
Comprehensive Cancer Guidelines.
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from RP, when LT types are compared (RP vs RT). It is
important to consider study limitations until ongoing
clinical trials confirm the proposed benefits.
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Huland.
Acquisition of data: Leyh-Bannurah, Gazdovich, Zaffuto.
Analysis and interpretation of data: Leyh-Bannurah, Karakiewicz, Zaffuto,
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